Cision PR Newswire

Awaken the Five Senses in Tianjin — A slower way to discover the city from Four Seasons Hotel Tianjin

TIANJIN, China, Aug. 28, 2026 /PRNewswire/ -- Thirty minutes from Beijing by high-speed train, Tianjin runs on a very different clock. While other cities compete over speed and skylines, Tianjin has made an art of taking life as it comes. The Haihe River runs through its center, the Bohai...

Alibaba’s Amap Introduces ABot-Recon, Reconstructing 10,000-Frame-Scale 3D Scenes From Just 12 Frames in Real Time

BEIJING, Aug. 28, 2026 /PRNewswire/ -- Amap, Alibaba's location-based services platform, today released ABot-Recon,...

Singclean 2nd Leaders Summit Charts New Course in Global Aesthetics

SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Hosted within the IMCAS China Conference venue at W...

Beauty Farm 1H2026 Net Profit Surges 40%, Reinforcing Its Industry Leadership

1H2026 Performance Highlights: Revenue reached RMB1.88 billion, up 29.0% year-on-year...

Aker Horizons ASA: Fourth-quarter results 2024

FORNEBU, Norway, Feb. 13, 2025 /PRNewswire/ -- Aker Horizons ASA (OSE: AKH), a developer of green energy and industry, today announced results for the fourth quarter...

Cloud4C Secures Dual AI Specializations on Microsoft Azure, Strengthening AI Capabilities

SINGAPORE, Feb. 13, 2025 /PRNewswire/ -- Cloud4C, a global leader in AI-driven cloud and cybersecurity services, has achieved two prestigious AI specializations on Microsoft...

DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has...

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003

SUZHOU, China, Feb. 13, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase...